Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Carl Zielinski et al. · The Lancet · 2009
Cited by 1,114 works. doi:10.1016/s0140-6736(09)61497-5
Authors
- Tudor–Eliade Ciuleanu
- Thomas Brodowicz
- Christoph Carl Zielinski
- Joo Hang Kim
- Maciej Jerzy Krzakowski
- Eckart Laack
- Yi-Long Lung Cancer Wu
- Isabel Bover
- Stephen D. Begbie
- Valentina Tzekova
- Branka Čučević
- José Rodrigues Pereira
- Sung Hyun Yang
- Jayaprakash Madhavan
- Katherine P. Sugarman
- Patrick M. Peterson
- William J. John
- Kurt Krejcy
- Chandra Prakash Belani
References
- Global cancer statistics
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- AJCC Cancer Staging Manual
- Analysis of Binary Data
- Global Cancer Statistics, 2002
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy